{
  "pmcid": "PMC11971672",
  "pmid": "40184070",
  "title": "Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial",
  "overall_score": 0.515460668420419,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 40,
        "items": [
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Carriers of CYP2C19 loss-of-function alleles (intermediate or poor metabolizers: *1/*2, *1/*3, *2/*17, *3/*17, *2/*2, *2/*3, *3/*3) had a higher incidence of the composite cardiovascular outcome (recurrent stroke, myocardial infarction, cardiovascular death) at 6 months compared with extensive metabolizers (*1/*1, *1/*17, *17/*17): 2.7% (49/1785) vs 1.6% (18/1125); log-rank P = .048; multivariable HR for noncarriers vs carriers 0.58 (95% CI 0.33\u20130.99, P = .049).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "This prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel. The risk of cardiovascular events within 6 months was significantly lower in LOF allele noncarriers (1.6%) than in LOF allele carriers (2.7%) (log-rank *P* = .048)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Carriers of CYP2C19 loss-of-function alleles (intermediate or poor metabolizers: *1/*2, *1/*3, *2/*17, *3/*17, *2/*2, *2/*3, *3/*3) had a higher incidence of the composite cardiovascular outcome (recurrent stroke, myocardial infarction, cardiovascular death) at 6 months compared with extensive metabolizers (*1/*1, *1/*17, *17/*17): 2.7% (49/1785) vs 1.6% (18/1125); log-rank P = .048; multivariable HR for noncarriers vs carriers 0.58 (95% CI 0.33\u20130.99, P = .049).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "This prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel. The risk of cardiovascular events within 6 months was significantly lower in LOF allele noncarriers (1.6%) than in LOF allele carriers (2.7%) (log-rank *P* = .048)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Carriers of CYP2C19 loss-of-function alleles (intermediate or poor metabolizers: *1/*2, *1/*3, *2/*17, *3/*17, *2/*2, *2/*3, *3/*3) had a higher incidence of the composite cardiovascular outcome (recurrent stroke, myocardial infarction, cardiovascular death) at 6 months compared with extensive metabolizers (*1/*1, *1/*17, *17/*17): 2.7% (49/1785) vs 1.6% (18/1125); log-rank P = .048; multivariable HR for noncarriers vs carriers 0.58 (95% CI 0.33\u20130.99, P = .049).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "This prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel. The risk of cardiovascular events within 6 months was significantly lower in LOF allele noncarriers (1.6%) than in LOF allele carriers (2.7%) (log-rank *P* = .048)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Carriers of CYP2C19 loss-of-function alleles (intermediate or poor metabolizers: *1/*2, *1/*3, *2/*17, *3/*17, *2/*2, *2/*3, *3/*3) had a higher incidence of the composite cardiovascular outcome (recurrent stroke, myocardial infarction, cardiovascular death) at 6 months compared with extensive metabolizers (*1/*1, *1/*17, *17/*17): 2.7% (49/1785) vs 1.6% (18/1125); log-rank P = .048; multivariable HR for noncarriers vs carriers 0.58 (95% CI 0.33\u20130.99, P = .049).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "This prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel. The risk of cardiovascular events within 6 months was significantly lower in LOF allele noncarriers (1.6%) than in LOF allele carriers (2.7%) (log-rank *P* = .048)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Recurrent stroke within 6 months occurred more frequently in CYP2C19 LOF allele carriers vs noncarriers: 2.5% (45/1785) vs 1.4% (16/1125); log-rank P = .047; HR ~0.56 (95% CI 0.32\u20131.00, reported for noncarriers vs carriers).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of recurrent stroke with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of recurrent stroke with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "However, stroke recurrence was more frequent in the LOF allele carrier group (45 [2.5%]) than in the LOF allele noncarrier group (16 [1.4%]) (HR, 0.56; 95% CI, 0.32-1.00; P = .047).",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "In this nonrandomized clinical trial, patients who were CYP2C19 LOF allele carriers and were treated with clopidogrel had a higher likelihood of experiencing cardiovascular events after ischemic stroke than did noncarriers."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Recurrent stroke within 6 months occurred more frequently in CYP2C19 LOF allele carriers vs noncarriers: 2.5% (45/1785) vs 1.4% (16/1125); log-rank P = .047; HR ~0.56 (95% CI 0.32\u20131.00, reported for noncarriers vs carriers).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of recurrent stroke with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of recurrent stroke with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "However, stroke recurrence was more frequent in the LOF allele carrier group (45 [2.5%]) than in the LOF allele noncarrier group (16 [1.4%]) (HR, 0.56; 95% CI, 0.32-1.00; P = .047).",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "In this nonrandomized clinical trial, patients who were CYP2C19 LOF allele carriers and were treated with clopidogrel had a higher likelihood of experiencing cardiovascular events after ischemic stroke than did noncarriers."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Recurrent stroke within 6 months occurred more frequently in CYP2C19 LOF allele carriers vs noncarriers: 2.5% (45/1785) vs 1.4% (16/1125); log-rank P = .047; HR ~0.56 (95% CI 0.32\u20131.00, reported for noncarriers vs carriers).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of recurrent stroke with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of recurrent stroke with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "However, stroke recurrence was more frequent in the LOF allele carrier group (45 [2.5%]) than in the LOF allele noncarrier group (16 [1.4%]) (HR, 0.56; 95% CI, 0.32-1.00; P = .047).",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "In this nonrandomized clinical trial, patients who were CYP2C19 LOF allele carriers and were treated with clopidogrel had a higher likelihood of experiencing cardiovascular events after ischemic stroke than did noncarriers."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Recurrent stroke within 6 months occurred more frequently in CYP2C19 LOF allele carriers vs noncarriers: 2.5% (45/1785) vs 1.4% (16/1125); log-rank P = .047; HR ~0.56 (95% CI 0.32\u20131.00, reported for noncarriers vs carriers).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are associated with increased risk of recurrent stroke with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of recurrent stroke with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "However, stroke recurrence was more frequent in the LOF allele carrier group (45 [2.5%]) than in the LOF allele noncarrier group (16 [1.4%]) (HR, 0.56; 95% CI, 0.32-1.00; P = .047).",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "In this nonrandomized clinical trial, patients who were CYP2C19 LOF allele carriers and were treated with clopidogrel had a higher likelihood of experiencing cardiovascular events after ischemic stroke than did noncarriers."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Ischemic stroke events as a secondary outcome were numerically higher in LOF allele carriers but not statistically significant: 2.4% (42/1785) vs 1.4% (15/1125); P = .06.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with increased risk of ischemic stroke events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of ischemic stroke events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).",
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, with no significant difference (*P* = .06)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Ischemic stroke events as a secondary outcome were numerically higher in LOF allele carriers but not statistically significant: 2.4% (42/1785) vs 1.4% (15/1125); P = .06.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with increased risk of ischemic stroke events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of ischemic stroke events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).",
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, with no significant difference (*P* = .06)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Ischemic stroke events as a secondary outcome were numerically higher in LOF allele carriers but not statistically significant: 2.4% (42/1785) vs 1.4% (15/1125); P = .06.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with increased risk of ischemic stroke events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of ischemic stroke events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).",
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, with no significant difference (*P* = .06)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Ischemic stroke events as a secondary outcome were numerically higher in LOF allele carriers but not statistically significant: 2.4% (42/1785) vs 1.4% (15/1125); P = .06.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with increased risk of ischemic stroke events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of ischemic stroke events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).",
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, with no significant difference (*P* = .06)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in myocardial infarction between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.2% (2/1125); P = .64.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of myocardial infarction with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of myocardial infarction with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cBased on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\u201d",
                "\u201cThe primary outcome measure was the difference in cardiovascular events (stroke, including ischemic or hemorrhagic, myocardial infarction, or cardiovascular death) within 6 months after an ischemic stroke between patients categorized as carrier or noncarrier of the *CYP2C19* LOF allele.\u201d",
                "\u201c[Table 2] reports the incidence rate for effectiveness and safety outcomes. There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.\u201d\n\nand from Table 2:\n\n\u201cMyocardial infarction: 4 (0.1); LOF allele carrier 2 (0.1); LOF allele noncarrier 2 (0.2); *P* = .64.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in myocardial infarction between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.2% (2/1125); P = .64.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of myocardial infarction with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of myocardial infarction with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cBased on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\u201d",
                "\u201cThe primary outcome measure was the difference in cardiovascular events (stroke, including ischemic or hemorrhagic, myocardial infarction, or cardiovascular death) within 6 months after an ischemic stroke between patients categorized as carrier or noncarrier of the *CYP2C19* LOF allele.\u201d",
                "\u201c[Table 2] reports the incidence rate for effectiveness and safety outcomes. There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.\u201d\n\nand from Table 2:\n\n\u201cMyocardial infarction: 4 (0.1); LOF allele carrier 2 (0.1); LOF allele noncarrier 2 (0.2); *P* = .64.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in myocardial infarction between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.2% (2/1125); P = .64.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of myocardial infarction with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of myocardial infarction with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cBased on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\u201d",
                "\u201cThe primary outcome measure was the difference in cardiovascular events (stroke, including ischemic or hemorrhagic, myocardial infarction, or cardiovascular death) within 6 months after an ischemic stroke between patients categorized as carrier or noncarrier of the *CYP2C19* LOF allele.\u201d",
                "\u201c[Table 2] reports the incidence rate for effectiveness and safety outcomes. There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.\u201d\n\nand from Table 2:\n\n\u201cMyocardial infarction: 4 (0.1); LOF allele carrier 2 (0.1); LOF allele noncarrier 2 (0.2); *P* = .64.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in myocardial infarction between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.2% (2/1125); P = .64.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of myocardial infarction with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of myocardial infarction with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cBased on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\u201d",
                "\u201cThe primary outcome measure was the difference in cardiovascular events (stroke, including ischemic or hemorrhagic, myocardial infarction, or cardiovascular death) within 6 months after an ischemic stroke between patients categorized as carrier or noncarrier of the *CYP2C19* LOF allele.\u201d",
                "\u201c[Table 2] reports the incidence rate for effectiveness and safety outcomes. There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.\u201d\n\nand from Table 2:\n\n\u201cMyocardial infarction: 4 (0.1); LOF allele carrier 2 (0.1); LOF allele noncarrier 2 (0.2); *P* = .64.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in cardiovascular death between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.0% (0/1125); P = .53.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of cardiovascular death with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of cardiovascular death with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.",
                "Cardiovascular death | 2 (0.1) | 2 (0.1) | 0 (0.0) | .53"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in cardiovascular death between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.0% (0/1125); P = .53.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of cardiovascular death with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of cardiovascular death with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.",
                "Cardiovascular death | 2 (0.1) | 2 (0.1) | 0 (0.0) | .53"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in cardiovascular death between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.0% (0/1125); P = .53.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of cardiovascular death with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of cardiovascular death with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.",
                "Cardiovascular death | 2 (0.1) | 2 (0.1) | 0 (0.0) | .53"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "No significant difference in cardiovascular death between LOF allele carriers and noncarriers: 0.1% (2/1785) vs 0.0% (0/1125); P = .53.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of cardiovascular death with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of cardiovascular death with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "There was no significant difference between the LOF allele carrier and noncarrier groups regarding the occurrence of myocardial infarction and cardiovascular-related death.",
                "Cardiovascular death | 2 (0.1) | 2 (0.1) | 0 (0.0) | .53"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Good functional outcome (mRS 0\u20132 at 3 months) did not differ between LOF allele carriers and noncarriers: 81.7% vs 81.9%; P = .89.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered likelihood of good functional outcome (modified Rankin Scale 0\u20132 at 3 months) with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "likelihood of good functional outcome with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\"Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\"",
                "\"The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.\"",
                "\"mRS 0-2 at 3 mo\t2170 (81.8)\t1329 (81.7)\t841 (81.9)\t.89\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Good functional outcome (mRS 0\u20132 at 3 months) did not differ between LOF allele carriers and noncarriers: 81.7% vs 81.9%; P = .89.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered likelihood of good functional outcome (modified Rankin Scale 0\u20132 at 3 months) with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "likelihood of good functional outcome with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\"Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\"",
                "\"The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.\"",
                "\"mRS 0-2 at 3 mo\t2170 (81.8)\t1329 (81.7)\t841 (81.9)\t.89\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Good functional outcome (mRS 0\u20132 at 3 months) did not differ between LOF allele carriers and noncarriers: 81.7% vs 81.9%; P = .89.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered likelihood of good functional outcome (modified Rankin Scale 0\u20132 at 3 months) with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "likelihood of good functional outcome with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\"Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\"",
                "\"The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.\"",
                "\"mRS 0-2 at 3 mo\t2170 (81.8)\t1329 (81.7)\t841 (81.9)\t.89\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Good functional outcome (mRS 0\u20132 at 3 months) did not differ between LOF allele carriers and noncarriers: 81.7% vs 81.9%; P = .89.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered likelihood of good functional outcome (modified Rankin Scale 0\u20132 at 3 months) with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "likelihood of good functional outcome with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\"Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).\"",
                "\"The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and deterioration of neurologic symptoms within 7 days or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.\"",
                "\"mRS 0-2 at 3 mo\t2170 (81.8)\t1329 (81.7)\t841 (81.9)\t.89\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Early neurologic deterioration (END) within 7 days did not differ significantly (5.8% in LOF carriers vs 4.9% in noncarriers; P = .33).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of early neurologic deterioration with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of early neurologic deterioration with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and **deterioration of neurologic symptoms within 7 days** or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, **with no significant difference (P = .06). Other outcomes were not significantly different between the groups (Table 2).**",
                "Table 2. \u2026 END  160 (5.5)  104 (5.8)  56 (4.9)  .33"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Early neurologic deterioration (END) within 7 days did not differ significantly (5.8% in LOF carriers vs 4.9% in noncarriers; P = .33).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of early neurologic deterioration with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of early neurologic deterioration with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and **deterioration of neurologic symptoms within 7 days** or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, **with no significant difference (P = .06). Other outcomes were not significantly different between the groups (Table 2).**",
                "Table 2. \u2026 END  160 (5.5)  104 (5.8)  56 (4.9)  .33"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Early neurologic deterioration (END) within 7 days did not differ significantly (5.8% in LOF carriers vs 4.9% in noncarriers; P = .33).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of early neurologic deterioration with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of early neurologic deterioration with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and **deterioration of neurologic symptoms within 7 days** or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, **with no significant difference (P = .06). Other outcomes were not significantly different between the groups (Table 2).**",
                "Table 2. \u2026 END  160 (5.5)  104 (5.8)  56 (4.9)  .33"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "Early neurologic deterioration (END) within 7 days did not differ significantly (5.8% in LOF carriers vs 4.9% in noncarriers; P = .33).",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of early neurologic deterioration with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of early neurologic deterioration with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "The secondary outcome was the difference in the development of ischemic stroke, transient ischemic attack without brain imaging lesions, myocardial infarction, coronary artery revascularization procedures within 6 months, and **deterioration of neurologic symptoms within 7 days** or good functional outcome at 3 months after the initial stroke (modified Rankin scale 0-2) between carrier and noncarrier of the LOF allele.",
                "Regarding secondary outcomes, ischemic stroke events occurred in 42 patients (2.4%) in the LOF allele carrier group and 15 (1.4%) patients in the LOF allele noncarrier group, **with no significant difference (P = .06). Other outcomes were not significantly different between the groups (Table 2).**",
                "Table 2. \u2026 END  160 (5.5)  104 (5.8)  56 (4.9)  .33"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Major bleeding events were not significantly different between LOF allele carriers and noncarriers: 0.6% (11/1785) vs 0.8% (9/1125); HR 1.29 (95% CI 0.53\u20133.13); P = .56.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of major bleeding with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of major bleeding with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "No significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).",
                "There was no significant difference between the 2 groups regarding the occurrence of a major bleeding event (11 of 1785 [0.6%] in LOF allele carriers and 9 of 1125 [0.8%] in LOF allele noncarriers; HR, 1.29; 95% CI, 0.53-3.13; *P* = .56), noncardiogenic death (3 [0.2%]) in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.53; 95% CI, 0.56-5.08; *P* = .58).",
                "In our study, the risk of major bleeding among LOF allele carriers (0.6%) was not significantly greater than that among noncarriers (0.8%) (HR, 1.29; 95% CI, 0.53-3.13; *P* = .56)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Major bleeding events were not significantly different between LOF allele carriers and noncarriers: 0.6% (11/1785) vs 0.8% (9/1125); HR 1.29 (95% CI 0.53\u20133.13); P = .56.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of major bleeding with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of major bleeding with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "No significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).",
                "There was no significant difference between the 2 groups regarding the occurrence of a major bleeding event (11 of 1785 [0.6%] in LOF allele carriers and 9 of 1125 [0.8%] in LOF allele noncarriers; HR, 1.29; 95% CI, 0.53-3.13; *P* = .56), noncardiogenic death (3 [0.2%]) in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.53; 95% CI, 0.56-5.08; *P* = .58).",
                "In our study, the risk of major bleeding among LOF allele carriers (0.6%) was not significantly greater than that among noncarriers (0.8%) (HR, 1.29; 95% CI, 0.53-3.13; *P* = .56)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Major bleeding events were not significantly different between LOF allele carriers and noncarriers: 0.6% (11/1785) vs 0.8% (9/1125); HR 1.29 (95% CI 0.53\u20133.13); P = .56.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of major bleeding with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of major bleeding with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "No significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).",
                "There was no significant difference between the 2 groups regarding the occurrence of a major bleeding event (11 of 1785 [0.6%] in LOF allele carriers and 9 of 1125 [0.8%] in LOF allele noncarriers; HR, 1.29; 95% CI, 0.53-3.13; *P* = .56), noncardiogenic death (3 [0.2%]) in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.53; 95% CI, 0.56-5.08; *P* = .58).",
                "In our study, the risk of major bleeding among LOF allele carriers (0.6%) was not significantly greater than that among noncarriers (0.8%) (HR, 1.29; 95% CI, 0.53-3.13; *P* = .56)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Major bleeding events were not significantly different between LOF allele carriers and noncarriers: 0.6% (11/1785) vs 0.8% (9/1125); HR 1.29 (95% CI 0.53\u20133.13); P = .56.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of major bleeding with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of major bleeding with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "No significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).",
                "There was no significant difference between the 2 groups regarding the occurrence of a major bleeding event (11 of 1785 [0.6%] in LOF allele carriers and 9 of 1125 [0.8%] in LOF allele noncarriers; HR, 1.29; 95% CI, 0.53-3.13; *P* = .56), noncardiogenic death (3 [0.2%]) in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.53; 95% CI, 0.56-5.08; *P* = .58).",
                "In our study, the risk of major bleeding among LOF allele carriers (0.6%) was not significantly greater than that among noncarriers (0.8%) (HR, 1.29; 95% CI, 0.53-3.13; *P* = .56)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "All-cause mortality within 6 months did not differ significantly: 0.3% (5/1785) in LOF allele carriers vs 0.1% (1/1125) in noncarriers; HR 0.31 (95% CI 0.04\u20132.71); P = .27.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of all-cause mortality with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of all-cause mortality with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cNo significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).\u201d",
                "\u201cIn addition, there was no significant difference in all-cause mortality (5 [0.3%] in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.31; 95% CI, 0.04-2.71; *P* = .27 for log-rank test) ([Figure 2](#zoi250037f2)).\u201d",
                "\u201cThis prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "All-cause mortality within 6 months did not differ significantly: 0.3% (5/1785) in LOF allele carriers vs 0.1% (1/1125) in noncarriers; HR 0.31 (95% CI 0.04\u20132.71); P = .27.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of all-cause mortality with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of all-cause mortality with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cNo significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).\u201d",
                "\u201cIn addition, there was no significant difference in all-cause mortality (5 [0.3%] in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.31; 95% CI, 0.04-2.71; *P* = .27 for log-rank test) ([Figure 2](#zoi250037f2)).\u201d",
                "\u201cThis prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "All-cause mortality within 6 months did not differ significantly: 0.3% (5/1785) in LOF allele carriers vs 0.1% (1/1125) in noncarriers; HR 0.31 (95% CI 0.04\u20132.71); P = .27.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of all-cause mortality with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of all-cause mortality with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cNo significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).\u201d",
                "\u201cIn addition, there was no significant difference in all-cause mortality (5 [0.3%] in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.31; 95% CI, 0.04-2.71; *P* = .27 for log-rank test) ([Figure 2](#zoi250037f2)).\u201d",
                "\u201cThis prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "All-cause mortality within 6 months did not differ significantly: 0.3% (5/1785) in LOF allele carriers vs 0.1% (1/1125) in noncarriers; HR 0.31 (95% CI 0.04\u20132.71); P = .27.",
              "Sentence": "CYP2C19 loss-of-function allele carriers (intermediate or poor metabolizers) are not associated with altered risk of all-cause mortality with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 loss-of-function allele noncarriers (extensive metabolizers).",
              "Alleles": "LOF carrier (intermediate or poor metabolizer)",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of all-cause mortality with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "LOF noncarrier (extensive metabolizer)",
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "\u201cNo significant differences were observed between *CYP2C19* LOF allele carriers and noncarriers regarding the occurrence of major bleeding (0.6% [11 of 1785] vs 0.8% [9 of 1125]; *P* = .56) and all-cause mortality (0.3% [5] vs 0.1% [1]; *P* = .27).\u201d",
                "\u201cIn addition, there was no significant difference in all-cause mortality (5 [0.3%] in LOF allele carriers and 1 [0.1%] in LOF allele noncarriers; HR, 0.31; 95% CI, 0.04-2.71; *P* = .27 for log-rank test) ([Figure 2](#zoi250037f2)).\u201d",
                "\u201cThis prospective, multicenter, large, nonrandomized PLATELET clinical trial evaluated the primary outcome of cardiovascular events according to the *CYP2C19* genotype in patients with acute ischemic stroke treated with clopidogrel.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*1",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "When comparing intermediate metabolizers (*1/*2, *1/*3, *2/*17, *3/*17) to poor metabolizers (*2/*2, *2/*3, *3/*3) among clopidogrel-treated patients, there was no significant difference in the primary composite cardiovascular outcome (adjusted HR 0.96; 95% CI 0.49\u20131.88; P = .92).",
              "Sentence": "CYP2C19 intermediate metabolizer genotypes are not associated with altered risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 poor metabolizer genotypes.",
              "Alleles": "intermediate metabolizer genotypes vs poor metabolizer genotypes",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "poor metabolizer genotypes",
              "Comparison Metabolizer types": "poor metabolizer",
              "Citations": [
                "When comparing the intermediate metabolizer group with the poor metabolizer group as the reference, there was no significant difference in the occurrence of the primary outcome (HR, 0.96; 95% CI, 0.49-1.88; P = .92).",
                "Based on the result of CYP2C19 genotyping (*1, *2, *3, and *17 alleles), we defined extensive metabolizers as patients with *1/*1, *1/*17, and *17/*17 genotypes; intermediate metabolizers as patients with only one *2 or *3 genotypes (*1/*2, *1/*3, *2/*17, and *3/*17); and poor metabolizers as patients with only *2 or *3 genotypes (*2/*2, *2/*3, and *3/*3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*2",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "When comparing intermediate metabolizers (*1/*2, *1/*3, *2/*17, *3/*17) to poor metabolizers (*2/*2, *2/*3, *3/*3) among clopidogrel-treated patients, there was no significant difference in the primary composite cardiovascular outcome (adjusted HR 0.96; 95% CI 0.49\u20131.88; P = .92).",
              "Sentence": "CYP2C19 intermediate metabolizer genotypes are not associated with altered risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 poor metabolizer genotypes.",
              "Alleles": "intermediate metabolizer genotypes vs poor metabolizer genotypes",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "poor metabolizer genotypes",
              "Comparison Metabolizer types": "poor metabolizer",
              "Citations": [
                "When comparing the intermediate metabolizer group with the poor metabolizer group as the reference, there was no significant difference in the occurrence of the primary outcome (HR, 0.96; 95% CI, 0.49-1.88; P = .92).",
                "Based on the result of CYP2C19 genotyping (*1, *2, *3, and *17 alleles), we defined extensive metabolizers as patients with *1/*1, *1/*17, and *17/*17 genotypes; intermediate metabolizers as patients with only one *2 or *3 genotypes (*1/*2, *1/*3, *2/*17, and *3/*17); and poor metabolizers as patients with only *2 or *3 genotypes (*2/*2, *2/*3, and *3/*3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*3",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "When comparing intermediate metabolizers (*1/*2, *1/*3, *2/*17, *3/*17) to poor metabolizers (*2/*2, *2/*3, *3/*3) among clopidogrel-treated patients, there was no significant difference in the primary composite cardiovascular outcome (adjusted HR 0.96; 95% CI 0.49\u20131.88; P = .92).",
              "Sentence": "CYP2C19 intermediate metabolizer genotypes are not associated with altered risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 poor metabolizer genotypes.",
              "Alleles": "intermediate metabolizer genotypes vs poor metabolizer genotypes",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "poor metabolizer genotypes",
              "Comparison Metabolizer types": "poor metabolizer",
              "Citations": [
                "When comparing the intermediate metabolizer group with the poor metabolizer group as the reference, there was no significant difference in the occurrence of the primary outcome (HR, 0.96; 95% CI, 0.49-1.88; P = .92).",
                "Based on the result of CYP2C19 genotyping (*1, *2, *3, and *17 alleles), we defined extensive metabolizers as patients with *1/*1, *1/*17, and *17/*17 genotypes; intermediate metabolizers as patients with only one *2 or *3 genotypes (*1/*2, *1/*3, *2/*17, and *3/*17); and poor metabolizers as patients with only *2 or *3 genotypes (*2/*2, *2/*3, and *3/*3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C19*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "CYP2C19*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": 40184070,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "When comparing intermediate metabolizers (*1/*2, *1/*3, *2/*17, *3/*17) to poor metabolizers (*2/*2, *2/*3, *3/*3) among clopidogrel-treated patients, there was no significant difference in the primary composite cardiovascular outcome (adjusted HR 0.96; 95% CI 0.49\u20131.88; P = .92).",
              "Sentence": "CYP2C19 intermediate metabolizer genotypes are not associated with altered risk of composite cardiovascular events with clopidogrel treatment in patients with acute ischemic stroke as compared to CYP2C19 poor metabolizer genotypes.",
              "Alleles": "intermediate metabolizer genotypes vs poor metabolizer genotypes",
              "Specialty Population": null,
              "Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of composite cardiovascular events with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "poor metabolizer genotypes",
              "Comparison Metabolizer types": "poor metabolizer",
              "Citations": [
                "When comparing the intermediate metabolizer group with the poor metabolizer group as the reference, there was no significant difference in the occurrence of the primary outcome (HR, 0.96; 95% CI, 0.49-1.88; P = .92).",
                "Based on the result of CYP2C19 genotyping (*1, *2, *3, and *17 alleles), we defined extensive metabolizers as patients with *1/*1, *1/*17, and *17/*17 genotypes; intermediate metabolizers as patients with only one *2 or *3 genotypes (*1/*2, *1/*3, *2/*17, and *3/*17); and poor metabolizers as patients with only *2 or *3 genotypes (*2/*2, *2/*3, and *3/*3)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.8490325504293045,
      "total_samples": 4,
      "ground_truth_annotations": {
        "count": 4,
        "matched_count": 4,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.9772659659385681,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19*2",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*17 + *17/*17"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*2",
                "prediction": "CYP2C19*2",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*2",
                "score": 0.9252737760543823,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Composite cardiovascular events, Efficacy:Recurrent stroke",
                "score": 0.936795711517334,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "CYP2C19*1/*1, CYP2C19*1/*17, CYP2C19*17/*17 (LOF noncarriers)",
                "score": 0.9105901718139648,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.9758677363395691,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19*3",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*17 + *17/*17"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*3",
                "prediction": "CYP2C19*3",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*3",
                "score": 0.9112914800643921,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Composite cardiovascular events, Efficacy:Recurrent stroke",
                "score": 0.936795711517334,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "CYP2C19*1/*1, CYP2C19*1/*17, CYP2C19*17/*17 (LOF noncarriers)",
                "score": 0.9105901718139648,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.782402902841568,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*17 + *17/*17"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*1",
                "prediction": "CYP2C19*1/*1",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*1/*1",
                "score": 0.9644790291786194,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "decreased",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Composite cardiovascular events, Efficacy:Recurrent stroke",
                "score": 0.936795711517334,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2, CYP2C19*2/*3, CYP2C19*3/*3, CYP2C19*2/*17, CYP2C19*3/*17 (LOF carriers)",
                "score": 0.9227542877197266,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.778684425354004,
            "annotation": {
              "Variant/Haplotypes": "CYP2C19*1",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*17 + *17/*17"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2C19*1",
                "prediction": "CYP2C19*17/*17",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2C19",
                "prediction": "CYP2C19",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "clopidogrel",
                "prediction": "clopidogrel",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
                "prediction": "*17/*17",
                "score": 0.9272942543029785,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "decreased",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
                "prediction": "Efficacy:Composite cardiovascular events, Efficacy:Recurrent stroke",
                "score": 0.936795711517334,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1 + *1/*17 + *17/*17",
                "prediction": "CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2, CYP2C19*2/*3, CYP2C19*3/*3, CYP2C19*2/*17, CYP2C19*3/*17 (LOF carriers)",
                "score": 0.9227542877197266,
                "match_status": "partial_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 1,
        "items": [
          {
            "variant": "CYP2C19*1/*17",
            "gene": "CYP2C19",
            "drug": "clopidogrel",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2C19*1/*17",
              "Gene": "CYP2C19",
              "Drug(s)": "clopidogrel",
              "PMID": "40184070",
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "Extensive metabolizers (*1/*1, *1/*17, *17/*17; LOF noncarriers) had lower risk of composite cardiovascular events than LOF carriers (2.7% vs 1.6%; HR for noncarriers vs carriers 0.58, 95% CI 0.34-0.99, P=.049 in multivariable model).",
              "Sentence": "CYP2C19*1/*17 is associated with decreased risk of Composite cardiovascular events, Efficacy:Recurrent stroke when treated with clopidogrel in people with Disease:Acute ischemic stroke.",
              "Alleles": "*1/*17",
              "Specialty Population": null,
              "Metabolizer types": "extensive metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Efficacy:Composite cardiovascular events, Efficacy:Recurrent stroke",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Acute ischemic stroke",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2, CYP2C19*2/*3, CYP2C19*3/*3, CYP2C19*2/*17, CYP2C19*3/*17 (LOF carriers)",
              "Comparison Metabolizer types": "intermediate metabolizer, poor metabolizer",
              "PMID_norm": "40184070",
              "Variant Annotation ID_norm": "4",
              "Citations": [
                "Based on the result of *CYP2C19* genotyping (**1*, **2*, **3*, and **17* alleles), we defined extensive metabolizers as patients with **1/*1*, **1/*17*, and **17/*17* genotypes; intermediate metabolizers as patients with only one **2* or **3* genotypes (**1/*2*, **1/*3*, **2/*17*, and **3/*17*); and poor metabolizers as patients with only **2* or **3* genotypes (**2/*2*, **2/*3*, and **3/*3*). In line with the study protocol, we dichotomized patients into the LOF allele carrier (intermediate or poor metabolizer group) and LOF allele noncarrier (extensive metabolizer group).^3,10,11^",
                "Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days.",
                "The risk of cardiovascular events within 6 months was significantly lower in LOF allele noncarriers (1.6%) than in LOF allele carriers (2.7%) (log-rank *P* = .048). Stroke recurrence was more common among LOF allele carriers (2.5%) than noncarriers (1.4%)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs12248560",
                "variant_id": "PA166154147",
                "confidence": 0.9473684210526315
              },
              "Drug(s)_normalized": {
                "normalized": "clopidogrel",
                "drug_id": "PA449053",
                "confidence": 1.0
              }
            }
          }
        ]
      }
    },
    "study_parameters": {
      "score": 0.7882938480377197,
      "total_samples": 2,
      "ground_truth_annotations": {
        "count": 2,
        "matched_count": 2,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.7007825164233937,
            "annotation": {
              "Study Parameters ID": 1453096140,
              "Variant Annotation ID": 1453096120,
              "Study Type": "clinical trial",
              "Study Cases": 2910.0,
              "Study Controls": null,
              "Characteristics": "PLATELET trial, Recurrent stroke",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.047",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.56,
              "Confidence Interval Start": 0.32,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": "Unknown"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1453096140,
                "prediction": 2,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1453096120,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 2910.0,
                "prediction": 1785,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1125,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "PLATELET trial, Recurrent stroke",
                "prediction": "CYP2C19 loss-of-function allele carriers vs noncarriers among Korean patients with acute ischemic stroke treated with clopidogrel; recurrent stroke within 6 months",
                "score": 0.9133027791976929,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.047",
                "prediction": "= 0.047",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.56,
                "prediction": 0.56,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.32,
                "prediction": 0.32,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 1.0,
                "prediction": 1.0,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6903242742314059,
            "annotation": {
              "Study Parameters ID": 1453096116,
              "Variant Annotation ID": 1453096120,
              "Study Type": "clinical trial",
              "Study Cases": 2910.0,
              "Study Controls": null,
              "Characteristics": "PLATELET trial, composite outcome (recurrent stroke, myocardial infarction, and all-cause mortality at 180 days)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.048",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.58,
              "Confidence Interval Start": 0.34,
              "Confidence Interval Stop": 1.0,
              "Biogeographical Groups": "Unknown"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1453096116,
                "prediction": 1,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1453096120,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "clinical trial",
                "prediction": "clinical trial",
                "score": 1.0,
                "match_status": "match"
              },
              "Study Cases": {
                "ground_truth": 2910.0,
                "prediction": 1785,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": 1125,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "PLATELET trial, composite outcome (recurrent stroke, myocardial infarction, and all-cause mortality at 180 days)",
                "prediction": "CYP2C19 loss-of-function allele carriers vs noncarriers among Korean patients with acute ischemic stroke treated with clopidogrel; primary composite cardiovascular outcome within 6 months",
                "score": 0.9355126619338989,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.048",
                "prediction": "= 0.048",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 0.58,
                "prediction": 0.58,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.34,
                "prediction": 0.33,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 1.0,
                "prediction": 0.99,
                "score": 0.9,
                "match_status": "partial_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Unknown",
                "prediction": "East Asian",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 7,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 3,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 1785,
              "Study Controls": 1125,
              "Characteristics": "CYP2C19 loss-of-function allele carriers vs noncarriers among Korean patients with acute ischemic stroke treated with clopidogrel; major bleeding within 6 months",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.56",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.29,
              "Confidence Interval Start": 0.53,
              "Confidence Interval Stop": 3.13,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 4,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 1785,
              "Study Controls": 1125,
              "Characteristics": "CYP2C19 loss-of-function allele carriers vs noncarriers among Korean patients with acute ischemic stroke treated with clopidogrel; noncardiogenic death within 6 months",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.58",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.53,
              "Confidence Interval Start": 0.56,
              "Confidence Interval Stop": 5.08,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 5,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 1785,
              "Study Controls": 1125,
              "Characteristics": "CYP2C19 loss-of-function allele carriers vs noncarriers among Korean patients with acute ischemic stroke treated with clopidogrel; all-cause mortality within 6 months",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.27",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.31,
              "Confidence Interval Start": 0.04,
              "Confidence Interval Stop": 2.71,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 6,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": null,
              "Study Controls": null,
              "Characteristics": "Among smokers with acute ischemic stroke on clopidogrel, CYP2C19 loss-of-function allele noncarriers vs carriers; primary composite cardiovascular outcome within 6 months",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.02",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.09,
              "Confidence Interval Start": 0.01,
              "Confidence Interval Stop": 0.64,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 7,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 1391,
              "Study Controls": 394,
              "Characteristics": "Intermediate metabolizers (one CYP2C19*2 or *3 allele) vs poor metabolizers (two loss-of-function alleles) among Korean patients with acute ischemic stroke treated with clopidogrel; primary composite cardiovascular outcome within 6 months",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.92",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.96,
              "Confidence Interval Start": 0.49,
              "Confidence Interval Stop": 1.88,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 8,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": null,
              "Study Controls": null,
              "Characteristics": "Intermediate metabolizers vs poor metabolizers among Korean patients with acute ischemic stroke treated with aspirin plus clopidogrel; primary composite cardiovascular outcome within 6 months",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.98",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.99,
              "Confidence Interval Start": 0.5,
              "Confidence Interval Stop": 1.93,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 9,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 1785,
              "Study Controls": 1125,
              "Characteristics": "CYP2C19 loss-of-function allele noncarriers vs carriers among Korean patients with acute ischemic stroke treated with clopidogrel; primary composite cardiovascular outcome within 6 months (multivariable Cox model)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.049",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.58,
              "Confidence Interval Start": 0.33,
              "Confidence Interval Stop": 0.99,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}